16 Melanoma 1 1 0 13 13 1378 http://clinicaltrials.dfhcc.harvard.edu/trials/1378 Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma The purpose of the study is to determine if ipilimumab is effective in preventing or delaying recurrence and prolongs survival after complete resection of high risk stage III melanoma Recruiting 16 Melanoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/16-melanoma Phase 3 267 http://clinicaltrials.dfhcc.harvard.edu/trials/267 SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma The purpose of this study is to evaluate how effective SU011248 works in treating acral lentiginous and mucosal melanoma which has spread beyond the local region. SU011248 is a protein-tyrosine kinase inhibitor and acts as a c-kit inhibitor drug. It is believed to work by blocking signals on certain cancer cells which allow the malignant cells to multiply and spread due to a change in the genetic make up of the cancer cell. Recruiting 16 Melanoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/16-melanoma Phase 2 982 http://clinicaltrials.dfhcc.harvard.edu/trials/982 Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Solar Melanoma That Cannot Be Removed By Surgery RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with locally advanced or metastatic mucosal melanoma, acral melanoma, or solar melanoma that cannot be removed by surgery. Recruiting 16 Melanoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/16-melanoma Phase 2 65 http://clinicaltrials.dfhcc.harvard.edu/trials/65 A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies The purpose of this study is to determine the safety and effectiveness of MDX-1106 in patients with certain types of cancer. Another purpose is to determine how MDX-1106 is absorbed and distributed within the body, and how it's eventually eliminated. Recruiting 24 Prostate Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/24-prostate-cancer 16 Melanoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/16-melanoma 10 Kidney Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/10-kidney-cancer 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer Phase 1 124 http://clinicaltrials.dfhcc.harvard.edu/trials/124 Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of GC1008, a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in previously treated patients with locally advanced or metastatic renal cell carcinoma or malignant melanoma. Recruiting 16 Melanoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/16-melanoma 10 Kidney Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/10-kidney-cancer Phase 1 172 http://clinicaltrials.dfhcc.harvard.edu/trials/172 In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer The purpose of this research study is to determine whether we can purify and grow a population of cells from the participants blood (iNKT cells) and then safely give them back to the participant in increased numbers, and whether these cells will then stimulate the bodies own immune response against the cancer. These iNKT cells have been used in laboratory studies and information from these and other research studies suggest that increasing the number of these cells in the blood can stimulate the immune response against tumors. Recruiting 16 Melanoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/16-melanoma Phase 1 290 http://clinicaltrials.dfhcc.harvard.edu/trials/290 Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma The purpose of this research study is to determine the safety of using the study drugs bevacizumab and ipilimumab together, and the doses in combination which can be given to people safely. This study also seeks to investigate whether using both study drugs lengthens the amount of time before the participants melanoma worsens. Recruiting 16 Melanoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/16-melanoma Phase 1 368 http://clinicaltrials.dfhcc.harvard.edu/trials/368 A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma The purpose of this study is to determine the safety profile, pharmacokinetics, pharmacodynamics and maximum tolerated dose of RAF265 in patients with locally advanced and metastatic melanoma. Recruiting 16 Melanoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/16-melanoma Phase 1 1236 http://clinicaltrials.dfhcc.harvard.edu/trials/1236 A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor. The purpose of this clinical trial is to evaluate the benefit of the immunotherapeutic product GSK 2132231A in preventing disease relapse when given to melanoma patients, after surgical removal of their tumor. Recruiting 16 Melanoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/16-melanoma 1257 http://clinicaltrials.dfhcc.harvard.edu/trials/1257 A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma The purpose of this study is to evaluate the efficacy of ABT-888 in combination with Temozolomide versus Temozolomide alone in subjects with metastatic melanoma. Recruiting 16 Melanoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/16-melanoma 1300 http://clinicaltrials.dfhcc.harvard.edu/trials/1300 Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients To assess the efficacy in terms of overall survival of AZD6244 in combination with dacarbazine, compared with dacarbazine alone, in first line patients with BRAF mutation positive advanced cutaneous or unknown primary melanoma Recruiting 16 Melanoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/16-melanoma 1383 http://clinicaltrials.dfhcc.harvard.edu/trials/1383 Dinaciclib in Treating Patients With Stage IV Melanoma RATIONALE: Dinaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well dinaciclib works in treating patients with stage IV melanoma. Recruiting 16 Melanoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/16-melanoma 1410 http://clinicaltrials.dfhcc.harvard.edu/trials/1410 A Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma This open-label single arm study will assess the efficacy, safety and tolerability of RO5185426 in previously treated patients with metastatic melanoma. Patients will receive oral RO5185426 [RG7204; PLEXXIKON: PLX4032] at a dose of 960 mg b.i.d. continuously until disease progression or withdrawal from study and will be assessed at regular intervals for tumour response and tolerability. Target sample size is <100 patients. Recruiting 16 Melanoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/16-melanoma